Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

被引：10
|
作者：
Ettl, Johannes [1 ]
机构：
[1] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
来源：
BREAST CARE | 2016年 / 11卷 / 03期
关键词：
Advanced breast cancer; Palbociclib; CDK4/6; Endocrine therapy; Cell cycle; DEPENDENT KINASE 4/6; 1ST-LINE TREATMENT; SUBGROUP ANALYSIS; LETROZOLE L; PD; 0332991; PALOMA-1/TRIO-18; COMBINATION; TRIAL; EFFICACY; SAFETY;
D O I：
10.1159/000447417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [31] Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
    Thill, Marc
    Schmidt, Marcus
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [32] CDK4/6 inhibitors in advanced breast cancer, what is beyond?
    Mohammed, Amrallah A.
    Rashied, Hanaa
    Elsayed, Fifi Mostafa
    ONCOLOGY REVIEWS, 2019, 13 (02) : 125 - 133
  • [33] Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+HER2-Early Breast Cancer
    Raheem, Farah
    Ofori, Henry
    Simpson, Lacey
    Shah, Vishal
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (11) : 1258 - 1266
  • [34] Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
    Scheidemann, Erin R.
    Shajahan-Haq, Ayesha N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [35] Clarithromycin Interactions with Palbociclib (CDK4/6 Inhibitor)
    Hu, Xiuqiong
    Yang, Wei
    Liu, Lanjie
    Qin, Hua
    LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (07): : 1698 - 1707
  • [36] CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
    Lynce, Filipa
    Shajahan-Haq, Ayesha N.
    Swain, Sandra M.
    PHARMACOLOGY & THERAPEUTICS, 2018, 191 : 65 - 73
  • [37] Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
    Fang, Hehui
    Huang, Doudou
    Yang, Fang
    Guan, Xiaoxiang
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : CP8 - 297
  • [38] Glucose Metabolic Reprogramming of ER+ Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Mannelli, Michele
    Parri, Matteo
    Comito, Giuseppina
    Ippolito, Luigi
    Giannoni, Elisa
    Bonechi, Martina
    Benelli, Matteo
    Migliaccio, Ilenia
    Malorni, Luca
    Chiarugi, Paola
    Morandi, Andrea
    CELLS, 2020, 9 (03)
  • [39] Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2-and HER2+advanced breast cancer
    Wang, Jingru
    Dong, Xiaotong
    Ashby, Charles R.
    Chen, Zhe-Sheng
    Zhang, Yunxiang
    DRUGS OF THE FUTURE, 2022, 47 (12) : 867 - 886
  • [40] Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation
    Elazzazy, Shereen
    Al-Ziftawi, Nour Hisham
    Mohamed Ibrahim, Mohamed Izham
    Bujassoum, Salha
    Hamad, Anas
    FRONTIERS IN ONCOLOGY, 2024, 14
12345